Current Report Filing (8-k)
July 12 2021 - 08:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): July 8,
2021
Rennova
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
001-35141 |
|
68-0370244 |
(Commission
File Number) |
|
(I.R.S.
Employer Identification No.) |
400
South Australian Avenue, Suite 800,
West Palm
Beach, Florida.
|
|
33401 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(561)
855-1626 |
(Registrant’s
Telephone Number, Including Area Code) |
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered under Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which
registered |
None |
|
None |
|
None |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company [ ]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. [ ]
Item
8.01. Other Events.
On
July 8, 2021, the Board of Directors of Rennova Health, Inc. (the
“Company”) approved an amendment to the Company’s Certificate of
Incorporation (the “Amendment”), to effect a 1-for-1,000 reverse
stock split of the Company’s shares of common stock to be effective
on July 16, 2021. On June 15, 2021, the holders of a majority of
the total voting power of the Company’s securities approved an
amendment to the Company’s Certificate of Incorporation to effect a
reverse split of all of the Company’s shares of common stock at a
specific ratio within a range from 1-for-50 to 1-for-2,000, and
granted authorization to the Board of Directors to determine in its
discretion the specific ratio and timing of the reverse split on or
prior to December 31, 2021.
As a
result of the reverse stock split, every 1,000 shares of the
Company’s pre-reverse split common stock will be combined and
reclassified into one share of the Company’s common stock.
Proportionate voting rights and other rights of common stockholders
will not be affected by the reverse stock split, other than as a
result of the cash payment for any fractional shares that would
have otherwise been issued. Stockholders who would otherwise hold a
fractional share of common stock will receive a cash payment in
respect of such fraction of a share of common stock. No fractional
shares will be issued in connection with the reverse stock
split.
The
reverse stock split will become effective at 5:00 p.m., Eastern
Time, on July 16, 2021 and the Company’s common stock will trade on
a post-split basis at the open of business on July 19, 2021. The
par value and other terms of the common stock will not be affected
by the reverse stock split. The authorized capital of the Company
of 10,000,000,000 shares of common stock and 5,000,000 shares of
preferred stock, also will not be affected by the reverse
split.
All
outstanding preferred shares, stock options, warrants, and equity
incentive plans immediately prior to the reverse stock split will
generally be appropriately adjusted by dividing the number of
shares of common stock into which the preferred shares, stock
options, warrants and equity incentive plans are exercisable or
convertible by 1,000 and multiplying the exercise or conversion
price by 1,000, as a result of the reverse stock split.
The
Company’s transfer agent, Computershare Inc., is acting as exchange
agent for the reverse stock split and will send instructions to
stockholders of record regarding the exchange of certificates for
common stock.
Item
9.01. |
Financial
Statements and Exhibits. |
(d)
Exhibits
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
July 12, 2021 |
RENNOVA
HEALTH, INC. |
|
|
|
|
By: |
/s/
Seamus Lagan |
|
|
Seamus
Lagan |
|
|
Chief
Executive Officer |
|
|
(principal
executive officer) |
Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Jul 2022 to Aug 2022
Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Aug 2021 to Aug 2022